A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis (DR-TB) and provide access to effective cure and prevention of DR-TB throughout the world.

Over ten million people will develop tuberculosis (TB) in the world this year; over 500,000 of these will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and regimens involving new TB drugs in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

 


Developments in MDR-TB


WHO announces updates on new molecular assays for the diagnosis of TB and drug resistance

Posted on 16 Jan 2020
Significant improvements to the diagnosis of tuberculosis (TB) and rifampicin resistance in adults and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO

Webinar: Advocacy for access to DR-TB treatment – webinar materials now available online

Posted on 16 Jan 2020
The TB Europe Coalition conducted a webinar on 13 November 2019 on advocating for the new guidelines on drug-resistant TB (DR-TB) treatment.

For more news, click here.